#1 Clinical Trials Search in Europe

Naxitamab

Naxitamab is an innovative drug being studied in clinical trials for the treatment of high-risk neuroblastoma, a rare and aggressive childhood cancer. This article explores how Naxitamab is being used in various clinical trials to improve outcomes for patients with neuroblastoma, particularly those with refractory or relapsed disease. We’ll examine the drug’s potential benefits, its combination with other therapies, and the ongoing research to optimize its use in fighting this challenging cancer.

Table of Contents

What is Naxitamab?

Naxitamab, also known by its brand name Danyelza or hu3F8, is a type of medicine called a monoclonal antibody. It’s specifically designed to target and fight certain types of cancer cells[1]. Naxitamab is a humanized antibody, which means it’s been modified to be more similar to human antibodies, potentially making it less likely to be rejected by the body’s immune system.

How Does Naxitamab Work?

Naxitamab works by targeting a specific molecule called GD2, which is found on the surface of certain cancer cells, particularly in neuroblastoma. By attaching to GD2, naxitamab helps the body’s immune system recognize and attack these cancer cells[1]. This targeted approach is designed to be more effective against cancer cells while potentially causing fewer side effects compared to traditional chemotherapy.

What Conditions Does Naxitamab Treat?

Naxitamab is primarily used to treat a type of cancer called neuroblastoma. Neuroblastoma is a rare cancer that mostly affects children and typically starts in the nerve cells outside the brain. Specifically, naxitamab is used for:

  • High-risk neuroblastoma in children aged 1 year and older and adults[2]
  • Relapsed or refractory neuroblastoma (cancer that has come back or hasn’t responded well to other treatments)[3]
  • Neuroblastoma that has spread to the bone or bone marrow[1]

In some clinical trials, naxitamab is also being studied for its potential use in treating other cancers that express the GD2 molecule, such as certain types of soft tissue cancers[4].

How is Naxitamab Administered?

Naxitamab is given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein. The treatment is typically administered in a hospital or specialized cancer treatment center under the supervision of healthcare professionals experienced in cancer therapies[1]. The dosage and frequency of treatment can vary depending on the specific treatment plan, but often includes:

  • Multiple doses over several days, repeated in cycles
  • Treatment cycles that may be repeated every 3-4 weeks
  • Dosage based on the patient’s weight

Before each infusion, patients usually receive medications to help prevent or reduce potential side effects[1].

Naxitamab in Combination Therapies

Naxitamab is often used in combination with other treatments to enhance its effectiveness. Common combinations include:

  • GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor): This is a type of protein that helps stimulate the immune system and is frequently given alongside naxitamab[5].
  • Chemotherapy drugs: In some treatment plans, naxitamab is combined with chemotherapy drugs like irinotecan and temozolomide[6].
  • Isotretinoin: This medication, related to vitamin A, is sometimes used in combination with naxitamab for maintenance therapy[2].
  • Immunotherapy combinations: Some clinical trials are exploring the use of naxitamab with other immunotherapy drugs or natural killer cells to potentially enhance the immune system’s ability to fight cancer[7].

Current Clinical Trials

Several clinical trials are ongoing to further investigate the effectiveness and safety of naxitamab in various scenarios:

  • Using naxitamab during initial treatment (induction therapy) for newly diagnosed high-risk neuroblastoma[8]
  • Combining naxitamab with other drugs for relapsed or refractory neuroblastoma[9]
  • Exploring naxitamab as a maintenance therapy to prevent cancer recurrence[5]
  • Investigating naxitamab in combination with new drugs or immunotherapy approaches[3]

Potential Side Effects

Like all medications, naxitamab can cause side effects. Some of the most common or significant side effects may include:

  • Pain: This can occur during or after the infusion and may require pain medication[6].
  • Allergic reactions: These can range from mild to severe and may require close monitoring during treatment[1].
  • Hypertension (high blood pressure)[6]
  • Fever
  • Nausea or vomiting
  • Fatigue

Healthcare providers closely monitor patients during and after treatment to manage any side effects that may occur. It’s important for patients and caregivers to report any unusual symptoms or side effects to their medical team promptly.

Aspect Details
Drug Name Naxitamab (also known as hu3F8)
Type Humanized monoclonal antibody targeting GD2
Primary Conditions High-risk neuroblastoma, refractory/relapsed neuroblastoma
Administration Intravenous infusion, typically in cycles
Common Combinations GM-CSF, irinotecan, temozolomide, isotretinoin
Trial Phases Primarily Phase 2 studies
Key Outcomes Measured Overall Response Rate (ORR), Progression-Free Survival (PFS), Overall Survival (OS)
Safety Considerations Monitored for allergic reactions, pain, hypertension
Unique Features Being studied in various stages of treatment (induction, consolidation, maintenance)

FAQ

  • What is Naxitamab and how does it work? Naxitamab is a humanized monoclonal antibody that targets GD2, a molecule found on neuroblastoma cells. It works by helping the immune system recognize and attack cancer cells, potentially improving the body's ability to fight the disease.
  • In which types of neuroblastoma is Naxitamab being studied? Naxitamab is being studied primarily in high-risk neuroblastoma, including patients with refractory disease (not responding to initial treatment), relapsed disease, and those in first remission. It's also being investigated for use in Ewing's sarcoma.
  • How is Naxitamab administered in clinical trials? Naxitamab is typically administered intravenously (IV) in cycles, often on specific days within each cycle. It's frequently given in combination with GM-CSF (granulocyte-macrophage colony-stimulating factor) and sometimes with other chemotherapy drugs.
  • What are some potential side effects of Naxitamab? Common side effects can include pain, fever, and high blood pressure. More severe reactions like allergic responses may occur. Patients are closely monitored and often receive pre-medication to manage side effects.
  • How does Naxitamab compare to standard treatments for neuroblastoma? Naxitamab is being studied as an addition to standard treatments, with the goal of improving response rates and survival outcomes. Some trials are comparing it to historical controls to assess its potential benefits over current standard therapies.

Ongoing Clinical Trials on Naxitamab

  • Study on the Effectiveness and Safety of Naxitamab for Patients with Refractory Ewing’s Sarcoma

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study of Naxitamab and Sargramostim for High-Risk Neuroblastoma in Patients with Refractory Bone or Bone Marrow Disease

    Recruiting

    2 1 1
    Investigated drugs:
    Denmark France Germany Italy Spain

  • Naxitamab Added to Standard Induction Therapy for Children and Teenagers with Newly Diagnosed High-Risk Neuroblastoma

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Neuroblastoma: A type of cancer that develops from immature nerve cells, most commonly in infants and young children. It usually begins in the adrenal glands but can also develop in other areas of the abdomen and in the chest, neck, and near the spine.
  • GD2: A molecule found on the surface of neuroblastoma cells that is targeted by Naxitamab. GD2 is present in high amounts on most neuroblastoma cells, making it a good target for immunotherapy.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Naxitamab is a monoclonal antibody designed to bind to GD2 on neuroblastoma cells.
  • Refractory Disease: Cancer that does not respond to initial treatment. In the context of neuroblastoma, it refers to tumors that don't shrink or disappear after standard therapies.
  • Relapsed Disease: Cancer that returns after a period of improvement. For neuroblastoma patients, this means the cancer has come back after initial treatment appeared to be successful.
  • GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor): A protein that stimulates the production of white blood cells. In neuroblastoma treatment, it's often given with Naxitamab to enhance the immune response against cancer cells.
  • Induction Therapy: The first phase of treatment for cancer, aimed at reducing the amount of cancer in the body. In neuroblastoma, this typically involves intensive chemotherapy.
  • Consolidation Therapy: Treatment given after induction therapy to further reduce the number of cancer cells in the body. For neuroblastoma, this may include high-dose chemotherapy, surgery, and radiation.
  • Maintenance Therapy: Treatment given after consolidation therapy to help prevent the cancer from returning. Naxitamab is being studied as part of maintenance therapy for neuroblastoma.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment. This is an important measure of a treatment's effectiveness in clinical trials.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse. This is often used as an endpoint in cancer clinical trials.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive. This is a key measure of the effectiveness of cancer treatments.
  • Minimal Residual Disease (MRD): Small numbers of cancer cells that remain in the body during or after treatment. Detecting and measuring MRD can help predict the risk of relapse.
  • International Neuroblastoma Response Criteria (INRC): A standardized set of guidelines used to assess how well neuroblastoma responds to treatment. It helps researchers compare results across different studies and trials.

References

  1. https://clinicaltrials.gov/study/NCT05968768
  2. https://clinicaltrials.gov/study/NCT06047535
  3. https://clinicaltrials.gov/study/NCT06540963
  4. https://clinicaltrials.gov/study/NCT06013618
  5. https://clinicaltrials.gov/study/NCT04909515
  6. https://clinicaltrials.gov/study/NCT06438614
  7. https://clinicaltrials.gov/study/NCT05754684
  8. https://clinicaltrials.eu/trial/naxitamab-added-to-standard-induction-therapy-for-children-and-teenagers-with-newly-diagnosed-high-risk-neuroblastoma/
  9. https://clinicaltrials.gov/study/NCT04560166